Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZBIO Zenas BioPharma Inc.

交易中 09-21 14:23:34 EDT

32.54

+1.04

+3.29%

最高33.19	最低31.00	成交量16.44万
今开31.62	昨收31.50	日振幅6.95%
总市值21.21亿	流通市值14.65亿	总股本6,518万
成交额534.45万	换手率0.37%	流通股本4,502万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZBIO","market":"US","secType":"STK","nameCN":"Zenas BioPharma Inc.","latestPrice":32.535,"timestamp":1790015010065,"preClose":31.5,"halted":0,"volume":164418,"delay":0,"changeRate":0.03285714285714275,"floatShares":45024692,"shares":65176700,"eps":-9.052203,"marketStatus":"交易中","change":1.035,"latestTime":"09-21 14:23:34 EDT","open":31.62,"high":33.19,"low":31,"amount":5344453.12704,"amplitude":0.069524,"askPrice":32.54,"askSize":220,"bidPrice":32.5,"bidSize":19,"shortable":3,"etf":0,"ttmEps":-9.052203,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1790020800000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":31.5,"sharesOutstanding":249967,"nav":10.0592,"aum":2514468.0464,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":31.5,"preClose":31.5,"latestTime":"08:20 EDT","volume":2,"amount":63,"timestamp":1789993201254,"change":0,"changeRate":0,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":31.5,"preClose":31.5,"latestTime":"19:45 EDT","volume":496924,"amount":15653090.7129,"timestamp":1789775156728,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.212163,"impliedVol":0.4624,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/ZBIO","defaultTab":"news","newsList":[{"id":"1158836638","title":"Zenas BioPharma提交招股文件：卖股股东拟发售最高700万股普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1158836638","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158836638?lang=zh_cn&edition=full","pubTime":"2026-09-12 04:51","pubTimestamp":1789159869,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.已向美国证券交易委员会（SEC）提交文件，计划由卖股股东发售最多700万股普通股。这一消息源自该公司最新公布的监管申报文件。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194910745","title":"Zenas Biopharma宣布Obexelimab三期INDIGO试验达成主要及所有关键次要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=1194910745","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1194910745?lang=zh_cn&edition=full","pubTime":"2026-06-03 07:19","pubTimestamp":1780442370,"startTime":"0","endTime":"0","summary":"Zenas Biopharma Inc. 公布，其候选药物Obexelimab在针对免疫球蛋白G4相关疾病（IgG4-RD）的关键注册性三期INDIGO试验中，成功达成了主要终点以及所有关键的次要终点。\n相关数据已在2026年欧洲抗风湿病联盟（EULAR）大会上同步发布，并同期发表于《新英格兰医学杂志》。试验结果显示，Obexelimab治疗显著降低了糖皮质激素的使用剂量及其相关毒性。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107172672","title":"Zenas BioPharma公布Obexelimab治疗IgG4相关疾病关键3期INDIGO试验数据，同步亮相EULAR 2026大会并发表于《新英格兰医学杂志》","url":"https://stock-news.laohu8.com/highlight/detail?id=1107172672","media":"美股速递","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107172672?lang=zh_cn&edition=full","pubTime":"2026-06-03 07:05","pubTimestamp":1780441543,"startTime":"0","endTime":"0","summary":"Zenas BioPharma公司公布了其候选药物Obexelimab用于治疗免疫球蛋白G4相关疾病（IgG4-RD）的关键性3期INDIGO试验的完整数据。这一重要临床研究成果实现了双重发布：既在欧洲抗风湿病联盟2026年大会上进行了同步展示，也同时刊登在权威的《新英格兰医学杂志》上。\n该注册性3期试验达到了其主要终点和所有关键的次要终点，数据显示Obexelimab治疗为IgG4-RD患者带来了具有统计学意义和临床意义的显著改善。这一积极结果标志着该药物在应对这一慢性、免疫介导的纤维炎症性疾病方面迈出了关键一步，为该药的后续监管提交奠定了坚实基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110830833","title":"Zenas BioPharma宣布向美国FDA提交Obexelimab治疗IgG4-RD的生物制品许可申请","url":"https://stock-news.laohu8.com/highlight/detail?id=1110830833","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1110830833?lang=zh_cn&edition=full","pubTime":"2026-05-28 19:09","pubTimestamp":1779966556,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. 已正式向美国食品药品监督管理局提交了其候选药物Obexelimab用于治疗免疫球蛋白G4相关疾病的生物制品许可申请。此举标志着该药物在监管审批进程中迈出了关键一步。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120448524","title":"异动解读 | 泽纳斯生物制药盘前大涨6.45%，因将公布关键药物3期试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1120448524","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120448524?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:23","pubTimestamp":1779189818,"startTime":"0","endTime":"0","summary":"泽纳斯生物制药（ZBIO）今日盘前股价大涨6.45%，引起了市场的广泛关注。消息面上，公司宣布其针对奥贝昔利单抗在免疫球蛋白G4相关疾病治疗中的3期INDIGO注册试验结果，即将在2026年欧洲抗风湿病联盟大会上正式公布。这一关键数据的披露标志着该药物在应对这一复杂自身免疫性疾病方面取得了重要进展，INDIGO试验作为注册性研究，其成果对于评估药物的疗效与安全性至关重要，有望为患者带来新的治疗选择，因此吸引了全球风湿免疫学领域专家与投资者的密切关注。此次试验结果的公布被视为公司研发管线中的重要里程碑，市场预期积极的数据可能为药物未来的商业化铺平道路，从而推动了股价在盘前交易时段显著上扬。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107292388","title":"泽纳斯生物制药宣布将在2026年欧洲抗风湿病联盟大会上公布奥贝昔利单抗治疗IgG4相关疾病的3期INDIGO注册试验结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1107292388","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1107292388?lang=zh_cn&edition=full","pubTime":"2026-05-19 19:06","pubTimestamp":1779188794,"startTime":"0","endTime":"0","summary":"泽纳斯生物制药公司近日宣布，其针对奥贝昔利单抗在免疫球蛋白G4相关疾病治疗中的3期INDIGO注册试验结果，即将在2026年欧洲抗风湿病联盟大会上正式公布。这一关键数据的披露，标志着该药物在应对这一复杂自身免疫性疾病方面取得了重要进展。INDIGO试验作为一项注册性研究，其成果对于评估奥贝昔利单抗的疗效与安全性至关重要，有望为IgG4-RD患者带来新的治疗选择。公司计划在大会上详细展示试验数据，届时将吸引全球风湿免疫学领域的专家与投资者的密切关注。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103707231","title":"Zenas Biopharma宣布其潜在同类最佳口服IL-17Aa/Af抑制剂ZB021完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1103707231","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1103707231?lang=zh_cn&edition=full","pubTime":"2026-05-13 18:52","pubTimestamp":1778669521,"startTime":"0","endTime":"0","summary":"Zenas BioPharma公司宣布，其新型、潜在同类最佳的口服IL-17Aa/Af抑制剂ZB021的1期临床试验已完成首例受试者给药。\n该里程碑标志着这款旨在治疗多种自身免疫性疾病的候选药物正式进入临床开发阶段。IL-17A是驱动多种炎症性疾病病理过程的关键细胞因子，ZB021作为一种口服抑制剂，旨在精准靶向其特定亚型Aa和Af，有望为患者提供一种新的治疗选择。\n公司对推进该项目的临床开发充满期待，以评估其安全性、耐受性及药代动力学特性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123848176","title":"Zenas BioPharma完成3亿美元融资：发行可转债与普通股，加速自免药物开发","url":"https://stock-news.laohu8.com/highlight/detail?id=1123848176","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1123848176?lang=zh_cn&edition=full","pubTime":"2026-03-27 12:13","pubTimestamp":1774584809,"startTime":"0","endTime":"0","summary":"Zenas BioPharma完成3亿美元融资：发行可转债与普通股，加速自免药物开发生物制药公司Zenas BioPharma宣布，已完成同时公开发行2032年到期的2.50%可转换优先票据和普通股，募集资金总额达3亿美元。公司计划将净收益主要用于推进obexelimab的全球三期临床试验，以及其他早期自免候选药物的研究。自免疾病赛道竞争加剧Zenas BioPharma专注于开发针对自身免疫性疾病的创新疗法。此次融资将为Zenas提供充足的资金跑道，支持其关键临床试验的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133548955","title":"Zenas BioPharma Inc. 融资收益将用于支持Obexelimab美国上市、管线推进及一般企业用途","url":"https://stock-news.laohu8.com/highlight/detail?id=1133548955","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133548955?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:03","pubTimestamp":1774555391,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc. 近日宣布，其通过融资所获收益将专项用于支持其核心产品Obexelimab在美国市场的商业化上市准备工作。此外，部分资金也将用于推动公司研发管线的进一步拓展，以及其他一般企业运营目的。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ZBIO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148820224","title":"Zenas BioPharma宣布拟同步公开发行2032年到期可转换优先票据及普通股","url":"https://stock-news.laohu8.com/highlight/detail?id=1148820224","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148820224?lang=zh_cn&edition=full","pubTime":"2026-03-27 04:02","pubTimestamp":1774555361,"startTime":"0","endTime":"0","summary":"Zenas BioPharma Inc.披露了同步进行两项公开募资的计划：发行2032年到期的可转换优先票据，以及公司普通股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ZBIO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136169257","title":"异动解读 | 生物科技新星Zenas BioPharma首秀大涨11.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=1136169257","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1136169257?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:00","pubTimestamp":1726246829,"startTime":"0","endTime":"0","summary":"今日,生物科技公司Zenas BioPharma Inc. 在纳斯达克成功完成IPO,股价大涨11.71%,引发市场关注。当日Zenas IPO发行价为17美元,开盘股价则为18.35美元,较发行价溢价8%。Zenas在本次IPO中发行1320万股,募集资金2.25亿美元,超过了原计划规模。随着美国IPO新股市场近期回温,投资者对Zenas这样前景可期的生物科技股青睐有加,均有望成为推动其当日首秀股价大涨的重要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZBIO"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.zenasbio.com","stockEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":0.008},{"period":"3month","weight":0.5925},{"period":"6month","weight":0.4126},{"period":"1year","weight":0.6187},{"period":"ytd","weight":-0.1325}],"compareEarnings":[{"period":"1week","weight":-0.0034},{"period":"1month","weight":-0.0096},{"period":"3month","weight":0.02},{"period":"6month","weight":0.1744},{"period":"1year","weight":0.1501},{"period":"ytd","weight":0.117}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Zenas BioPharma, Inc.最初于2019年11月12日在开曼注册成立，名称为Zenas BioPharma（Cayman）Limited。2023年8月2日，该公司在特拉华州成立，同时将其名称从Zenas BioPharma（Cayman）Limited更改为Zenas BioPharma, Inc.。该公司是一家临床阶段的全球生物制药公司，致力于为有需要的患者开发和商业化基于免疫的变革疗法。随着对自身免疫性疾病发病机制的不断了解，以及有前景的基于免疫学的药理学靶点的扩展，他们正在建立一家专注于免疫学和炎症（“I&I”）的生物制药公司。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.066193},{"month":2,"riseRate":0.4,"avgChangeRate":-0.014847},{"month":3,"riseRate":0.6,"avgChangeRate":-0.027723},{"month":4,"riseRate":0.5,"avgChangeRate":0.001823},{"month":5,"riseRate":0.75,"avgChangeRate":0.218705},{"month":6,"riseRate":0.25,"avgChangeRate":-0.082782},{"month":7,"riseRate":0.2,"avgChangeRate":-0.126333},{"month":8,"riseRate":0.6,"avgChangeRate":0.033743},{"month":9,"riseRate":0.5,"avgChangeRate":0.044898},{"month":10,"riseRate":0.6,"avgChangeRate":0.128289},{"month":11,"riseRate":0,"avgChangeRate":-0.164546},{"month":12,"riseRate":0.4,"avgChangeRate":0.053544}],"exchange":"NASDAQ","name":"Zenas BioPharma Inc.","nameEN":"Zenas BioPharma Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Zenas BioPharma Inc.,ZBIO,Zenas BioPharma Inc.股票,Zenas BioPharma Inc.股票老虎,Zenas BioPharma Inc.股票老虎国际,Zenas BioPharma Inc.行情,Zenas BioPharma Inc.股票行情,Zenas BioPharma Inc.股价,Zenas BioPharma Inc.股市,Zenas BioPharma Inc.股票价格,Zenas BioPharma Inc.股票交易,Zenas BioPharma Inc.股票购买,Zenas BioPharma Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Zenas BioPharma Inc.(ZBIO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Zenas BioPharma Inc.(ZBIO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}